Loading clinical trials...
Loading clinical trials...
Neo-adjuvant Intratumoral Anti-CTLA4 + Anti-PD1 in Patients With Localized Melanoma
Conditions
Interventions
Ipilimumab (YervoyTM, 50 mg/10 mL solution)
Nivolumab (OpdivoTM, 40 mg/4mL solution)
Locations
1
France
Gustave Roussy
Villejuif, France
Start Date
January 12, 2026
Primary Completion Date
December 1, 2027
Completion Date
December 1, 2033
Last Updated
February 11, 2026
NCT05111574
NCT07076550
NCT06999980
NCT04318717
NCT07155317
NCT07148245
Lead Sponsor
UNICANCER
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions